Information resources

Contact the AstraZeneca Information Center
Drug Assistance Programs
Request for Samples/Representative
Medical Education Grants Office (MEGO)

AstraZeneca Medicare Resources and Part D Outreach Tools:

• Finger Tip Formulary Tool
• Medicare Community Outreach Presentation [PowerPoint, 270KB]
• Making Sense of the Medicare Prescription Drug Coverage (Part D) [PDF, 2.47MB]
• Making Sense of the Medicare Prescription Drug Coverage (Part D) Customizable Version [PDF, 2.30MB]
• One Minute Consult Guide [PDF, 5.08MB]
• My Medicare Matters Web Card - English [PDF, 135KB]
• My Medicare Matters Web Card - Spanish [PDF, 112KB]

NOTE: AstraZeneca's Medicare resources and Part D Outreach Tools are provided for informational purposes only and are not intended to nor do they promote or advocate any particular Part D Plan. Part D beneficiaries should select the Part D Plan that they feel best meets their individual needs. AstraZeneca's Medicare resources and Part D Outreach Tools may NOT be utilized directly or indirectly with PDP or MA-PD plans. Thank you for honoring this requirement!

Web Sites for Health Care Professionals

Click here for our U.S. web sites

Current Product News

Date	Title
02/29/2008	AstraZeneca Submits sNDA For SEROQUEL XR™ For The Treatment Of Major Depressive Disorder
02/28/2008	FDA Approves NEXIUM® For The Treatment Of Short-Term GERD In Children 1 To 11 Years Old
01/02/2008	AstraZeneca Submits sNDAs For SEROQUEL XR™ For The Treatment Of Bipolar Mania And Bipolar Depression
12/14/2007	Data Show ARIMIDEX® (anastrozole) Continues To Be Superior To Tamoxifen In Helping Reduce The Risk Of Recurrence In Patients With Early Breast Cancer
12/10/2007	FDA concludes there is no increased risk of cardiac events for patients treated with omeprazole and NEXIUM® (esomeprazole magnesium)

More news